Iron chelators of the hydroxamate class arrest in vitro proliferation of malaria parasites and of mammalian cells. The factors determining the biological activity of the chelators have classically been attributed t o the chelators' capacity for binding iron and t o their ability t o traverse membranes as free chelators and as chelator-iron complexes. We show in this work that the nature of the chelatable pool of cell iron also contributes t o the susceptibility of cells t o iron chelators. A class of N-terminal (N,) derivatives of desferrioxamine (DFO), (N,-DFO), is shown here t o differentially affect growth and replication of intraerythrocytic parasites (Plasmodium falciparum). Methyl-anthranilic DFO (MADFOI, the relatively less hydrophilic member of the N,-DFOs series, The basis for its relatively high therapeutic index resides, in part, in the fact that animal cells can tolerate doses of chelator treatments that are demonstrably effective in reducing iron-load and can even cause transient cell metal deprivation. ' Indeed, in vitro studies indicated that such DFO treatments lead to a transient arrest in cell proliferation, primarily via blockage of obligatory deoxyribonucleotide synthesis." The cytostatic blockage has been attributed to the scavenging of intracellular iron,' which is presumed to be composed of low molecular weight iron@)-or iron(III)-complexes''3'2 (ie, chelatable iron pool). On chelator removal, iron is restored and nucleic acid synthesis is swiftly resumed. However, in the process of iron(I1) oxidatiodcomplexation by DFO, there is also a risk of oxidative radical f~rmation'~ that can also cause DNA breaks and induce apopt~sis.'~ These adverse properties of DFO, might contribute to some of the toxic effects of the drug, as previously reported.'
The basis for its relatively high therapeutic index resides, in part, in the fact that animal cells can tolerate doses of chelator treatments that are demonstrably effective in reducing iron-load and can even cause transient cell metal deprivation. ' Indeed, in vitro studies indicated that such DFO treatments lead to a transient arrest in cell proliferation, primarily via blockage of obligatory deoxyribonucleotide synthesis." The cytostatic blockage has been attributed to the scavenging of intracellular iron,' which is presumed to be composed of low molecular weight iron@)-or iron(III)-complexes''3'2 (ie, chelatable iron pool). On chelator removal, iron is restored and nucleic acid synthesis is swiftly resumed. However, in the process of iron(I1) oxidatiodcomplexation by DFO, there is also a risk of oxidative radical f~rmation'~ that can also cause DNA breaks and induce apopt~sis.'~ These adverse properties of DFO, might contribute to some of the toxic effects of the drug, as previously reported. ' In malaria infected cells, the major biological effect of DFO is cytotoxic rather than Thus, unlike mammalian cells that largely recover on DFO removal, parasites can neither replenish iron stores and resume metabolic activities, nor, apparently, can they discard and/or neutralize the chelator-metal These properties are associated with the restricted mode of iron acquisition by parasites from parasite-mediated degradation of host hemoglobin" and with DFO's differential permeation to parasitized red blood cells (RBCs).*O Ring stages, being essentially impermeant to DFO, are relatively insensitive to the drug, whereas trophozoite-schizonts, being markedly more permeable, are highly susceptible to it. These properties dictate the chemotherapeutic regimens, which comprise prolonged treatments' and expose the host to potentially deleterious drug effects. more hydrophilic N,-free DFO, displayed ICH, values of 21 f 5 pmol/L for parasites and 7 f 1 pmol/L for mammalian cells. The selective antiparasitic activity of MA-DFO, as reflected in the speed of action and IC,, values on cell proliferation, is attributed primarily t o membrane permeation and iron(ll1) binding properties of the drug. In contrast, the relatively low antiproliferative activity of the more permeant MA-DFO on mammalian cells, resulted from MA-DFO's reduced capacity for scavenging intracellular iron. This is apparent from MA-DFO reduced effects on: (1) the chelatable iron(ll1 pool that is associated with the cell cytosol; (2) the cell chelator-extractable iron, and (3) cell ferritin levels. The potent antimalarial efficacy and biological selectivity of MA-DFO relative t o the parent DFO, is of importance for improved design of chemotherapeutic agents. With the aim of understanding the selective nature of DFO effects on malaria parasites as compared to mammalian cells, we assessed several N-terminal derivatized DFOs (X-N,-DFOs) in terms of their effects on cellular iron stores and antiproliferative action. Preliminary studies indicated that N,-derivatization of DFO did not impair its iron(II1) binding properties.2032' The Nt-lipophilic substitution of DFO conferred to the chelator improved permeation capacity into infected cells and markedly higher antimalarial potency. However, the improved antimalarial efficacy of N,-DFOs, was also accompanied by a major reduction in the adverse action of DFOs on mammalian cells. Therefore, we have assessed whether the differential action of N,-DFOs might be associated with an apparently lower capacity of N, derivatized-DFOs, particularly methyl anthranilic (MA)-DFO, for affecting the cytosolic labile (or chelatable) iron pools of mammalian cells. Such differential performance of N,-DFO derivatives on parasites vis a vis mammalian cells, may provide new guides for improving the antimalarial drug perfor-
Parasite Cultures
Plasmodium falciparum, strain FCR-3 used for all experiments was maintained in Nunclon culture flasks (Nunc, Roskilde, Denmark) in human A' or 0' RBCs in RPMI 1640 medium (Biological Industries, Beth Haemek, Israel) supplemented with 25 mmol/L HEPES, 10 mmol/L glucose and 20 mmol/L NaHCO,, and 10% (vol/vol) heat inactivated A+ human plasma pooled from different blood donors. The cultivation method used was a modified version of Trager and Jensen's22 as described el~ewhere.'~ Parasitemia and growth stage distribution were determined on methanol fixed and Giemsa stained smears. Parasite growth synchronization and assessment of antimalarial activity of iron chelators were done as described previously. Is The compounds were added from concentrated stock solutions in dimethyl sulfoxide (DMSO) to microcultures (24 wells; Costar, Cambridge, MA) containing infected RBCs (2.5% hematocrit and 2 to 5% parasitemia). The cultures were synchronized to the ring stage by incubation in 300 mmol/L alanine and I O mmoVL Tris-HCI, pH 7.415 or by Percoll gradient centrifugation.2' After 18 to 24 hours exposure to the indicated drug, the cells were either supplemented directly with 6 pCi/mL of [3H]hypoxanthine or washed 3 times with large volume of RPMI 1640 medium and replenished with fresh growth medium before addition of the radiolabel, incubation for an additional 18 to 24 hours, and lysis by freezing. The freeze-thawed lysate of labeled cells was passed through glass fiber filters (Tamar Inc, Jerusalem, Israel). Incorporation of label into nucleic acid was measured in a Beckman Scintillation Counter (Beckman Corp. Fullerton, CA). All systems were run in hexatuplicates. The 50% inhibit05 concentrations (IC5') were determined by nonlinear least square fit to sigmoidal functions as described elsewhere.24 Statistical t-tests were performed according to the statistical package PCS (Pharmacologic Calculation System; Microcomputer Specialists, New York) based on the method of Tallarida and Murray.z4" The software program Microcal Origin (MicroCal Software Inc, Northampton, MA) was used for curve simulation and for graphic display.
Mammalian Cell Cultures
Mammalian cells were maintained in Nunclon culture flasks (Nunc) and grown at 37°C in a CO2-incubator (5% CO2) in 24-well plates (Nunc) as follows: human K562 erythroleukemia cells, as suspensions in a-Modified eagle's Medium (aMEM); human hepatoma cells (HepG2), as monolayers in Earle's MEM (EMEM) and Chinese hamster ovary cells (CHO), as monolayers in Dulbecco's MEM (DMEM). Cells in growing phase were exposed to iron chelators for 24 to 48 hours and assayed in duplicates for macromolecular synthesis (5-hour incorporation) of either [3H]-hypoxanthine or ['HIthymidine ( 5 pCilmL) into nucleic acids, respectively. K562 cells were processed with a Matrix cell harvester (Packard Instruments, Meriden, CT). Radiolabeled HepG2 and CHO cells were washed with isotonic buffer, fixed on the plates with ice-cold 5% trichloroacetic acid (TCA), and TCA precipitable materials were solubilized with 0.1N KOH and counted for radioactivity.
Total cell protein was estimated on 96 well plates either with the BCA method (Pierce Chemical CO, Rockford, IL) or the sulforhodamanine method as described elsewhere." The microplates were read in an enzyme linked immunosorbent assay (ELISA) Microplate EL 309 autoreader (Bio-Tek Instruments Inc, Winooski, VT) at the appropriate wavelengths.
Ferritin Assay
Cells (K562 or HepG2) grown in 12-well plates and treated with chelators for 24 hours, were washed with isotonic buffer and subsequently extracted with 300 pL Tris-HCI 10 mmoVL, NaCl 150 mmol/L, Triton X-100 (Sigma) ( O S % ) , NaN, (0.2%), pH 7.4 containing a cocktail of antiproteases as specified elsewhere.26 The extract was centrifuged at 2,OOOg X 10 minutes at 5°C and kept at 5°C. Aliquots were used for determinations of protein (BCA method, Pierce Chemical CO) and of femtin by fluorogenic ELISA, using rabbit antihuman spleen femtin antisera, and purified antiferritin antibodies conjugated to ~-galact~sidase.~' Femtin was also checked on immunoblots of samples run on Laemmli sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) (10 to 15% acrylamide) gelszx using rabbit antihuman placental femtin antibodies:' goat-antirabbit y globulin conjugated to horse radish peroxidase (Jackson Immunoresearch, West Grove, PA) in conjunction with enhanced chemiluminescence (ECL) detection (Radiochemical Center, Amersham, UK). 26 No attempts were made to discriminate between ferritin H and L subunits.
Iron Extraction Capacity of DFO Derivatives
K562 cells were preloaded for 1 hour with "Fe-difemc Transfenin (6.25 X IO6 dpmlnmole Fe, 0.05 pg/mL transferrin), extensively washed with complete growth medium and buffered saline solutions and incubated for 24 hours with the respective chelators in 24 well plates. The suspensions were separated into cell supemates (SI) and pellets by centrifugation. The pellets were extensively washed with full growth medium and buffered saline solutions, treated with 0.2% Triton X-100 (in 150 mmol/L NaCI, 20 mmol/L Tris-HC1, pH 7.4) supplemented with an antiprotease mixture. 26 An aliquot of the detergent-dispersed cells was taken for protein determination (BCA method, Pierce Chemical CO) and the remainder was centrifuged at 35,OOOg X 5 minutes. Radioactivity was counted in both cell supernate (Sl) and soluble (ie, supemate) fraction of detergent extract (supernate TS2) after decoloration with H202 (5%).
Chelation of Intracellular Iron: Assessment by a Fluorescent Method
Human erythroleukemia K562 cells were treated overnight with chelators in full growth medium, washed extensively and loaded with 0.125 pmol/L calcein-acetoxymethyl ester (calcein-AM) for 5 minutes at 37°C in HEPES-buffered, bicarbonate-free a-MEM medium containing 20 mmol/L HEPES, pH 7.3 (a-MEM-HEP) containing 1 mg/mL bovine serum albumin, washed from excess calcein-AM and resuspended in a-MEM-HEP Just before measurements, 1 mL of calcein loaded cell suspension (-5 X IOh cells) was centrifuged in a microcentrifuge and the cells were resuspended in 2 mL of prewarmed 150 mmol/L NaCI, 10 mmol/L For personal use only. on October 27, 2017. by guest www.bloodjournal.org From
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HEPES-Tris, pH 7.3 (HBS buffer). The cell suspension was transferred to a stirred, thermostated (37°C) cuvette, and fluorescence measurements were initiated. Fluorescence measurements (Exc. 488 nm, Em. 517 nm) were done in a PTI Spectrometry Station (Oscar configuration) (PhotoMed, Wedel, Germany), equipped with a temperature controlled cuvette holder and magnetic stirrer. The magnitude of the baseline fluorescent signal remained relatively stable throughout the measurements, the estimated leakage of the probe was lower than 10% per hour at 37°C. A fluorescence-quenching, anticalcein antibody (10 plkuvette) was added to eliminate all extracellular fluorescence, which amounted to -2% of the total fluorescence. The baseline signal under this condition remained stable for s20 minutes, indicating minimal leakage of the probe during the experimental period. At the indicated time, salicylaldehyde-isonicotinoyl hydrazone (SIH) was added (100 pmoVL final concentration), to obtain the maximal level of chelatable iron, as shown elsehere.^'.^'
RESULTS
The repertoire of DFOs used in this study comprises the hydrophilic DFO and its nitrilo derivative N-DFO and the less hydrophilic methylanthranilic derivative MA-DFO and the cyclic DFO-E (Fig 1) . Although these agents differ primarily in the nature of the substituent group at the terminal amino group, they display comparable binding affinities for iron(II1) (pKa 29-31) (measured as in ref 20).
Effect of DFOs on Macromolecule Synthesis in Parasitized Cells
P. falciparum infected cells were exposed to various concentrations of DFOs starting at mid-rings. After 24 hours 
Effect of DFO Derivatives on Mammalian Cells
The two human cell lines K562 and HepG2 (exponential growth phase) were
Nucleic acid and protein synthesis.
For Table 1 summarizes the calculated IC50 values for chelator effects on DNA, protein, and nucleic acid synthesis. Although quantitatively different, the rank order of inhibitory potencies was essentially similar for the three parameters: DFO was considerably more potent than all its derivatives on either mammalian cell line, whereas MA-DFO was the least potent of the four. The relative potencies of the two other DFO derivatives were intermediate to those of DFO and MA-DFO. We have found the IC50 values for drug effects on [3H]-thymidine incorporation into DNA particularly variable for HepG2 cells. Factors contributing to that phenomenon were found to be associated with the state of the culture, such as culture passage number, phase of cell growth and the time of exposure to drug. Most of the variability could be minimized by extending the drug exposure to 48 hours. As shown above for antimalarial activity, none of the structural congeners of DFO had any detectable effect on mammalian cells proliferation when administered as iron(II1) complexes (not shown).
Because the various DFOs differ in the lipophilic nature of the N-terminal group and therefore, in their putative permeation properties, we assessed whether any correlation existed between these drug properties and the onset of growth inhibition, ie, the drugs' speed of action (Fig 4) . For that purpose we followed the kinetics of nucleic acid synthesis in the presence of drugs' in both K562 and HepG2 cells. Cells exposed to a single concentration of 100 pmol/L DFO derivative were time monitored for [3H]-hypoxanthine incorporation into nucleic acid (Fig 4) . The onset of inhibition for all four DFO derivatives was between 4 to 6 hours, suggesting that permeation into cells per se did not apparently limit the rate of chelator action. This was found to be the case for the least potent of the drugs tested, MA-DFO. This fluorescent derivative'" accumulated in the cells within 4 to 6 hours, as visualized by fluorescence microscopy image analysis (not shown). The effect of DFOs on mammalian cells was also assessed in terms of cytosolic chelatable iron and cell ferritin levels. Both cell parameters provide a measure for the iron status in the cytosol. The first gives a direct measure of the chelatable metalzY.'o and the second indicates how changes in cytosolic iron affected ferritin levels.
(1) The cytosolic chelatable iron pool that might be affected by the various DFOs, was assessed with the recently developed fluorescence-quenching method based on the metal-sensor calcein.2y,"' K562 cells treated with DFOs were loaded with the fluorescent calcein. The initial level of fluorescence attained represents the amount of free calcein loaded into cells. The increase in fluorescence resulting from addition of the highly permeant chelator SIH provides an in situ measure for the chelatable iron pool in the cell. A typical experiment is depicted in Fig 5. Control cells showed a 0.25 pmol/L level of intracellular chelatable iron, as shown previously.'" After pretreatment with chelators, the basal level of cell fluorescence increased relative to control, as relatively less chelatable iron is present in cells. Consequently, the amount of fluorescence restored by SIH decreased. For all concentrations used (20 to 100 pmolk), DFO was considerably more potent than MA-DFO. The cell chelatable iron was reduced from 0.25 pmol/L to 0.013 to Cytosolic-chelatable iron (i) and ferritin levels (ii). Cells were exposed to various concentrations of chelators (3 to 100 pmol/L) for 48 hours and analyzed for DNA synthesis by 13Hlthymidine (T) incorporation, nucleic acid synthesis by [3Hlhypoxanthine (H) incorporation and total protein (P) by the sulforhodamine method, as described in the text. Data were analyzed as described in Fig 2, the ICso values (50% inhibitory concentrations) ( 0.04 ymol/L (85% to 95% reduction) after treatment with 20 ymolk DFO and to undetectable levels (+loo% reduction) by treatment with 100 ymol/L DFO. However, by equivalent treatments with MA-DFO, the chelatable iron pool of cells was considerably less affected: 42% and 74% reduction with 20 and 100 ymol/L, respectively. This clearly indicates that the relatively more permeant MA-DFO, was less efficient in intracellular chelation of iron than the parent, more hydrophilic DFO. Measurements of chelator extractable iron were also assessed in cells loaded with "Fe-trans-"I I Intracellular iron scavenging by DFOs as assessed with %on: K562 cells were loaded for 1 hour with 551ron-human transferrin, washed extensively with growth medium, and then incubated for 24 hours in growth medium alone (control) or in medium supplemented with DFOs at either 20 or 100 pmol/L. Radioactivity was measured in the medium and in cells following extensive washing. Data are given in terms of pmol-iron (using the 55iron-transferrin specific activity) per mg cell protein: in the medium (top scale) and in cells (bottom scale).
ferrin and analyzed for radioactivity in cells and medium (Fig 6) . Despite the relatively higher partition coefficient and permeation capacity of MA-DFO versus DFO,"' the latter was considerably more efficient than MA-DFO in extracting iron from cells. This was particularly reflected in the parameters obtained following a 24 hour treatment with 20 ymoll L chelator: the iron appearing in the medium was 1.7 5 .2 and 0.5 pmollmg protein after DFO and MA-DFO, respectively. The iron retained in the cells after 24 hour treatment was 26 5 I, 2 1 2 1, and 23 2 1 pmollmg protein, in control, DFO and MA-DFO treated cells, respectively.
(2) A similar pattern of chelator activities was observed with K562 and HepG2 cells analyzed for ferritin levels after a 24 hour incubation in the presence of chelators (Table 2) . For the E L S A method, we used rabbit antihuman spleen ferritin antibodies and rabbit antihuman placental ferritin antibodies. For SDS-PAGE (Westem) immunoblotting, we used rabbit antihuman spleen ferritin antibodies (Fig 7A and  B , respectively). The picture emerging from both assays was essentially equivalent. Supplementation of iron(II1) to the growth medium in the form of ferric ammonium citrate (FAC) induced a major increase in cytosolic ferritin levels. DFO markedly reduced cytosolic ferritin even at 20 pmol/ L concentrations, whereas the less hydrophilic MA-DFO, was considerably less effective. The other derivatives showed a pattem of effects similar to that obtained for iron extraction. These experiments indicate that in mammalian cells. the iron extraction capacity of the various DFOs is dictated not only by the partition coefficients, but also by their ability to form stable complexes with the chelatable iron form that prevails in cells.
DISCUSSION
Malaria parasites are among the most susceptible organisms to the action of iron chela tors"^"^"^'^ The mechanisms by which those chelators curb the proliferative capacity of parasites have recently been reviewed for hydroxamatebased chelators.'".'' They include primarily properties associated with the chelators, such as iron binding affinity and membrane partition coefficients of the free chelator and its iron complexes, which provide a measure of their membrane permeation properties.3' These properties can be assumed to be similar in parasite infected RBCs and mammalian cells, as previously shown.." However, the mode of action of the chelators on the different cell systems is associated with additional properties. These include: ( I ) the mechanisms of iron mobilization by the different cells; (2) the dependence of iron mobilization on the developmental stage of the cell or organism and (3) the nature of the chelatable form of bio-available iron that prevails in parasites as compared to mammalian cells.'" Parasites apparently differ from mammalian cells in all 3 properties, thus making them unique targets for iron chelating agents. The reversed siderophores used previously,".~'' and the DFOs used in this study, were found to irreversibly affect P fulciprirum growth in vitro, whereas all mammalian cells tested (K562, human hepatoma HepG2, human colon carcinoma HT-29, and CHO cells), fully recovered from 24 to 48 hour treatment with up to 100 p.mol/L chelators (not shown). We attributed these findings to the differential capacity of mammalian cells for restoring intracellular bio-available iron on drug rem~val'".'~."."~ and for removing the accumulated drug either in the free form or as drug-iron complexes. Because none of the drugs used had any effect on either parasite or mammalian cell proliferation when applied as iron complexes, we assume that their antiproliferative mode of action is most likely associated with their capacity to deprive cells of metabolic iron. However, at present, we cannot reject the possibility of in situ formation of toxic iron-chelator complexes. particularly in the unique parasite environment.".".7'
In this work we showed that differential effects of iron chelators on parasites versus mammalian cells can be more profound than previously described with RSFs.".I7 The effects were found with a series of N,-derivatives of the DFO family (Figs 2 and 3 and Table I ). First, their biological efficacy as suppressers of cell growth correlated with the putative permeation properties of the DFOs in parasites but not in mammalian cells. Second, the relatively low susceptibility of mammalian cells to MA-DFO (Fig 3 and Table 2 ). the most potent antimalarial N,-DFO tested, was apparently associated with the chemical nature of the iron present in the chelatable pool of the mammalian cell (Figs 5 and 6 ). In particular, MA-DFO, which has similar iron(ll1) binding affinity and even higher partition coefficient and membrane permeation capacity than DFO,'" was less effective than DFO in chelating and extracting intracellular iron from mammalian cells (Figs 5 and 6 ) and reducing the ferritin stores (Fig 7) .
The relatively lower cytotostatic potency of MA-DFO in mammalian cells, which correlates with its relatively lower effects on cell iron stores, could be attributed to several factors. Limited drug access into cells was highly unlikely, because MA-DFO was found to be demonstrably permeant to mammalian cells.2" The possible association of Nl-DFO properties with blockage of the terminal -NH2 group or modification of the pK, of cu IO'" in DFO to values >5 in MA-DFO or A-DF0'7 should be considered. Such a modification might confer on DFO different accessibility properties, which, in turn, might affect its accumulation in particular cell compartments or its interactions with the chelatable form of intracellular iron. The biological effects of the two other N-blocked or N-modified DFO derivatives provide some support for the previously discussed ideas. but do not necessarily prove them. However, alternative explanations should also be considered, such as specific intracellular modifications of the drugs or different interactions with the form of chelatable iron prevailing in cells, ie, iron(I1). Although the affinities of DFOs for iron(l1) are relatively small (<IOx) compared to those for iron(lI1) (ca. IO""), in ambient air, even iron(I1) might swiftly and avidly bind to DFO following hydroxamate-catalyzed oxidation to iron(lII).3x Thus, the caFor personal use only. on October 27, 2017. by guest www.bloodjournal.org From SELECTIVE CYTOXlClTY OF RON CHELATORS 4877 pacity of DFOs for forming stable complexes with the iron(I1) prevailing in might also depend on their capacity to induce oxidation to the iron(II1) form. This property might vary not only with the flexibility of the chelator backbone and the physicochemical nature of the N, group, but also with additional factors present in cells. Our in vitro studies of the interaction of DFO and MA-DFO with iron(I1) bound to the calcein, support only in part, such a notion. They indicate that MADFO's capacity for chelating cytosolic iron from mammalian cells, most of which is apparently in the iron(I1) form, is significantly lower than that of DF0.4' Although the reasons for the differential behavior of MA-DFO towards mammalian cells as compared to malaria infected cells remain to be fully elucidated, the implications of the results of the present work are highly relevant for future antimalarial drug design.
